Coherus and AbbVie settle Humira biosimilar dispute after Mark Cuban’s Cost Plus Drugs announcement

Biosimilars player Coherus Biosciences has patched things up with AbbVie after the pharma said Coherus violated its non-exclusive license to commercialize Yusimry, a biosimilar of Humira, a rheumatoid arthritis drug.

On June 6, Coherus received a notice from AbbVie because of Coherus’ announcement on June 1 of its pricing agreement with Mark Cuban Cost Plus Drug Company and its plans to offer Yusimry to Cost Plus Drugs customers beginning in July, according to SEC filings.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Jefferson Lab team explores proton therapy as a safer cancer treatment

Radiation therapy techniques have been used for more than a century to treat cancers. Physicists in the Radiation Detector and Imaging group and associated with

October 5, 2024

ADHD linked to risk for several common and serious mental health issues

The hyperactivity disorder, usually referred to as ADHD, is an independent risk factor for several common and serious mental health issues, finds research published in

September 6, 2023

Videra Health Secures 5.6M for AI-Powered Mental Health Screening & Monitoring

What You Should Know: – Videra Health, a frontrunner in AI-powered mental health assessments raises $5.6M in Seed II funding led by Peterson Ventures, with

May 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.